## Eastland Medical Systems LTD

## **ASX Release**

## Eastland's Board Restructure and New Board Member

Eastland Medical Systems Ltd (ASX: EMS) is pleased to announce a restructure of its Board. These changes will ensure that Eastland is well-equipped to effectively assess new opportunities as they are identified and to be in a position to commence a new growth phase.

The Board has appointed its current Chief Executive Officer, Mr. Stephen Carter, as its Executive Chairman. Mr. Carter has extensive pharmaceutical industry experience and has held a variety of senior positions with listed and un-listed public companies including roles of Chairman and Managing Director. He has extensive contacts and experience in the financial markets and the pharmaceutical industry and is highly qualified to lead executive management through the commercialisation process.

The Board is pleased to announce that Mr. Joseph Ohayon has joined the Board as an Executive Director. Mr. Ohayon joined Eastland Medical Systems Ltd in July 2010 as the Chief Financial Officer, and in March 2011 Joseph took over the role as Company Secretary. He has over 20 years' experience in financial roles including 12 years within health-related industries. Joseph qualified as a Chartered Accountant in the UK in 1987 and graduated with a Masters of Business Administration in International Business from Murdoch University in 2007.

Mr. Michael Stewart will remain on the Board as a Non-Executive Director. Mr. Stewart joined the Board of Eastland on 11 June 2009. He has a broad corporate and management background and has been extensively involved in bilateral donor funded and World Bank cofinanced Aid Projects in under-developed countries.

The Board will continue to look for an appropriately credentialed and experienced Non-Executive Director to add further value to the Eastland team.

As reported last week the shareholders have voted to change the name of the company to Suda Ltd. We are working to complete the name change in the shortest possible time. The Board sees the change of name as a pivotal point in the evolution of the Company and a message to the investment community that we are moving forward and shedding the shackles of the past.

ASX Release No. 589 4 December 2012 Page 1 of 2

As the ArTiMist™ project matures we have been looking to broaden our portfolio to provide greater potential return to our shareholders. These Board changes will complement the Company's efforts moving forward and the efforts of the past 12 months where we have assessed various new opportunities for the Company in areas such as cancer, vaccines and devices.

We have engaged a European consultant to identify potential opportunities, reviewed other investment opportunities within the pharmaceutical field and we are continuing to assess further projects. We look forward to the new opportunities that will come our way during this process and to the continued support of our loyal shareholders.

**Further information:** 

Stephen Carter Chief Executive Officer Director Eastland Medical Systems Ltd

Tel: +61 8 6142 5555

sjcarter@eastlandmedical.com.au